Maternal Serum Visfatin at 11–13 Weeks of Gestation in Gestational Diabetes Mellitus
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Visfatin and adiponectin are produced by adipose tissue and have opposite effects on insulin resistance. Circulating concentrations of these biomarkers are altered in type 2 diabetes mellitus. We sought to examine the potential value of maternal serum visfatin and adiponectin concentrations in early pregnancy as potential biomarkers in the prediction of gestational diabetes mellitus (GDM). METHODS: This work was a case-control study of 100 women who developed GDM and 300 nondiabetic controls. Maternal serum visfatin and adiponectin were measured between 11 and 13 weeks of gestation. Regression analysis in the nondiabetic group was performed to examine the maternal characteristics affecting the serum concentrations of visfatin and adiponectin. Likelihood ratios for GDM were calculated for visfatin and adiponectin, and performance of screening was assessed by using ROC curve analysis. RESULTS: In the GDM group compared with the nondiabetic group, the median maternal serum visfatin concentration was increased (1.34 multiples of the median [MoM], interquartile range [IQR] 0.70–2.87, vs 1.00 MoM, IQR: 0.53–1.92; P = 0.004) and serum adiponectin was decreased (0.66 MoM, IQR 0.50–0.92, vs 1.01, IQR 0.70–1.29; P < 0.0001). In screening for GDM by a combination of maternal factors and serum adiponectin and visfatin, the estimated detection rate was 68.0% (95% CI 58.3–76.3%), at a false-positive rate of 10%. CONCLUSIONS: At 11–13 weeks in pregnancies that develop GDM, the serum concentration of adiponectin is decreased and visfatin is increased, and these biomarkers can be combined with maternal factors to provide effective early screening for GDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
Snijders, R., Noble, P., Sebire, N., Souka, A., & Nicolaides, K. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11280-6 · Cited by 1,572
Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women
Catalano, P. M., Tyzbir, E. D., Roman, N. M., Amini, S. B., & Sims, E. A. H. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90012-g · Cited by 709
Catalano, P. M., Huston, L., Amini, S. B., & Kalhan, S. C. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70662-9 · Cited by 680
Williams, M. A., Qiu, C., Muy-Rivera, M., Vadachkoria, S., Song, T., & Luthy, D. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031201 · Cited by 220
Screening for biomarkers predictive of gestational diabetes mellitus
Georgiou, H. M., Lappas, M., Georgiou, G. M., Marita, A., Bryant, V. J., Hiscock, R., Permezel, M., Khalil, Z., & Rice, G. E. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0037-8 · Cited by 151
Cited by
Turning the Pyramid of Prenatal Care
Nicolaides, K. H. (2011) · Fetal Diagnosis and Therapy · doi:10.1159/000324320 · Cited by 357
Self-citationAbell, S., De Courten, B., Boyle, J., & Teede, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160613442 · Cited by 239
“While incremental sensitivity and specificity is seen by addition of inflammatory and other biomarkers to clinical tools for GDM [74,87,117,142], translation to clinically important improvements in prediction is debatable, with very few implementation studies performed.”
BackgroundAdipokines in gestational diabetes
Fasshauer, M., Blüher, M., & Stumvoll, M. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70176-1 · Cited by 230
Lorenzo-Almorós, A., Hang, T., Peiró, C., Soriano-Guillén, L., Egido, J., Tuñón, J., & Lorenzo, Ó. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0935-9 · Cited by 202
Biochemical and Molecular Biomarkers: Unraveling Their Role in Gestational Diabetes Mellitus
Karami, M., Mousavi, S. H., Rafiee, M., Heidari, R., & Shahrokhi, S. Z. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00980-8 · Cited by 33
Metadata
- Authors
- Ferreira, A. F. A., Rezende, J. C., Vaikousi, E., Akolekar, R., & Nicolaides, K. H.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-01
- Volume
- 57
- Issue
- 4
- Pages
- 609-613
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2107910174
- Cited by
- 86
- References
- 7
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maternal Serum Visfatin at 11–13 Weeks of Gestation in Gestational Diabetes Mellitus. https://app.cochat.ai/papers/10.1373/clinchem.2010.159806
- The paper
- Ferreira, A. F. A., Rezende, J. C., Vaikousi, E., Akolekar, R., & Nicolaides, K. H. (2011). Maternal Serum Visfatin at 11–13 Weeks of Gestation in Gestational Diabetes Mellitus. Clinical Chemistry. https://doi.org/10.1373/clinchem.2010.159806
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.